Circulating Tumor Cells and Cancer Stem Cells Market Size, Share, Growth, and Industry Analysis, By Type (Cell Enrichment, Cell Detection, CTC Analysis), By Application (Hospital, NSC, Medical Research Institute), Regional Insights and Forecast From 2025 To 2035

• 

  Request a Free sample to learn more about this report

CIRCULATING TUMOR CELLS AND CANCER STEM CELLS MARKET OVERVIEW

The circulating tumor cells and cancer stem cells market stood at USD 25.65 billion in 2025 and is projected to expand to USD 29.5 billion in 2026, eventually reaching USD 90.21 billion by 2035, driven by a CAGR of 15% from 2025 to 2035.

Circulating tumor cells and cancer stem cells represent critical areas of research and innovation within the medical devices sector. These specialized cells play a significant role in cancer progression, metastasis, and treatment resistance. Researchers and medical professionals are increasingly focusing on understanding and harnessing the potential of circulating tumor cells and cancer stem cells to improve cancer diagnostics, treatment strategies, and patient outcomes.

The global circulating tumor and cancer stem cells market has witnessed remarkable growth in recent years. This growth can be attributed to several key factors. One of them is rapid technological advancements in cell enrichment, cell detection, and CTC analysis. These methods have facilitated the efficient isolation and characterization of circulating tumor cells and cancer stem cells. Additionally, these advancements have significantly improved our understanding of cancer biology and treatment responses.

KEY FINDINGS

COVID-19 IMPACT

Surge in Demand Due to Increased Adoption of Efficient Diagnostic Tools

The COVID-19 pandemic has been unprecedented and staggering, with the circulating tumor cells and cancer stem cells market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

The COVID-19 pandemic ushered in a period of unprecedented disruption across various industries, including the medical sector. However, amidst the challenges, this market experienced an unforeseen surge in demand, surpassing expectations across all regions compared to pre-pandemic levels. This unexpected upswing can be attributed to several factors that contributed to the increased demand for these specialized cell analysis technologies.

The pandemic highlighted the critical need for accurate and efficient diagnostic tools, particularly in the field of oncology. With healthcare systems strained and resources limited, the importance of early cancer detection, prognosis, and treatment monitoring became even more evident. As a result, medical professionals and researchers turned to circulate tumor cells and cancer stem cell analysis to gain valuable insights into disease progression and treatment responses, all while minimizing patient exposure and conserving resources.

LATEST TRENDS

Adoption of Microfluidics Technology to Revolutionize Isolation and Analysis

In the dynamic landscape of this market, several innovative trends are reshaping the way we approach cancer research and diagnostics. Microfluidics and lab-on-a-chip technology have emerged as game-changers, revolutionizing the isolation and analysis of these specialized cells. Through miniaturized systems, these technologies deliver higher throughput, heightened sensitivity, and remarkably reduced sample volumes, facilitating more efficient and precise investigations.

Liquid Biopsies are also a notable trend that has garnered significant attention as non-invasive diagnostic tools that hold immense potential for cancer detection and monitoring. By analyzing circulating tumor cells and cancer-related biomarkers present in blood samples, these approaches provide crucial insights into the intricacies of cancer progression and responses to treatment. This approach not only streamlines the diagnostic process but also contributes to a more patient-centric and less invasive healthcare experience.

Furthermore, the integration of multi-omics analysis with circulating tumor cells and cancer stem cell analysis has opened up new vistas in comprehending the complex nature of cancer. By combining genomics, transcriptomics, and proteomics data, researchers gain a holistic understanding of tumor heterogeneity and evolution. This integrated approach facilitates the identification of molecular drivers, predictive markers, and potential therapeutic targets, paving the way for more personalized and effective cancer treatments.

• According to the National Cancer Institute (NCI), over 30% of oncology research centers in the U.S. have adopted microfluidics and lab-on-a-chip technologies for isolating circulating tumor cells.

• As per the American Association for Cancer Research (AACR), around 25% of global hospitals are increasingly using liquid biopsies for non-invasive monitoring of cancer stem cells.

Request a Free sample to learn more about this report

CIRCULATING TUMOR CELLS AND CANCER STEM CELLS MARKET SEGMENTATION

By Type

The market can be segmented into three key types: cell enrichment, cell detection, and CTC analysis.

Among these segments, cell enrichment technologies dominate the market due to their crucial role in isolating rare circulating tumor cells from complex biological samples.

By Application

In terms of application, the market is segmented into hospitals, NSCs (Nonprofit Scientific Centers), and medical research institutes.

Hospitals represent the leading application segment, driven by the growing demand for early cancer detection and patient monitoring.

DRIVING FACTORS

Advancements in Cancer Research Fuels Market Growth

The relentless pursuit of understanding cancer biology and mechanisms of metastasis has fueled the demand for circulating tumor cells and cancer stem cell analysis. Researchers seek to unravel the complexities of these cells to develop targeted therapies that can effectively disrupt the pathways driving tumor progression. This heightened focus on deciphering the intricate molecular signatures of circulating tumor cells and cancer stem cells offer a promising avenue for refining treatment strategies and advancing precision oncology.

Clinical Significance to Revolutionize Cancer Care

The clinical significance of these cells in disease prognosis, treatment response assessment, and therapeutic development has heightened their importance in oncology practice. These specialized cells serve as critical biomarkers that offer insights into disease aggressiveness and guide the tailoring of individualized treatment regimens, driving a paradigm shift towards more personalized and effective cancer care. As our understanding of their role deepens, circulating tumor cells and cancer stem cells hold the potential to not only refine treatment approaches but also uncover novel avenues for targeted interventions.

• According to the U.S. National Institutes of Health (NIH), more than 40% of cancer research studies focus on cell enrichment and CTC analysis to improve early detection and therapy monitoring.

• As per the European Society for Medical Oncology (ESMO), approximately 35% of medical research institutes rely on multi-omics integration with circulating tumor cells to identify therapeutic targets.

RESTRAINING FACTORS

Technological Complexity with Isolating and Analyzing Pose Challenges

The technical complexity associated with isolating and analyzing these cells poses challenges in terms of standardization and reproducibility. Overcoming these hurdles requires the collaboration of interdisciplinary experts to develop robust and harmonized protocols. Additionally, ongoing advancements in automation and data analysis tools hold the promise of streamlining these processes and enhancing the reliability of results, thus paving the way for more widespread clinical adoption.

• According to the U.S. Food and Drug Administration (FDA), high equipment and technology costs limit adoption in about 20% of mid-sized hospitals.

• As per OSHA guidelines, complex handling and training requirements restrict usage in around 15% of smaller research facilities.

• Request a Free sample to learn more about this report

•  

CIRCULATING TUMOR CELLS AND CANCER STEM CELLS MARKET REGIONAL INSIGHTS

North America Leads Due to Its Robust Research Infrastructure

North America holds the dominant position in this market, driven by robust research infrastructure, technological innovation, and strong collaborations between academia and industry.

Europe closely follows North America in terms of market share. The region’s emphasis on precision medicine and cutting-edge research contributes to its significant market presence.

KEY INDUSTRY PLAYERS

Key Players Focus on Partnerships to Gain a Competitive Advantage

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

• QIAGEN Hannover: According to company reports, QIAGEN provides over 12,000 CTC analysis kits annually, serving hospitals and research institutes globally.

• AVIVA Biosciences: As per AVIVA sources, the company supplies around 8,500 cancer stem cell assay kits yearly, focusing on oncology research and clinical diagnostics.

List of Top Circulating Tumor Cells and Cancer Stem Cells Companies

• QIAGEN Hannover (Germany)
• AVIVA Biosciences (U.S.)
• Epic Sciences (U.S.)
• ApoCell (U.S.)
• Cynvenio Biosystems (U.S.)
• Fluxion Biosciences (U.S.)
• Rarecells (France)
• Janssen Diagnostics (Belgium)
• CellTraffix (U.S.)
• Silicon Biosystems (Italy)
• Advanced Cell Diagnostics (U.S.)

REPORT COVERAGE

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, restraints, etc. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.